LibraryBy pinki shah / May 14, 2022 Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title of Presentation Type of Media — Video Document Audio Event 2024 Event — 2024 California Cancer Consortium Conference (CCC) 2024 MLS Cleveland 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 WCS Clear Displaying 1,776 - 1,800 of 2,711 « 1 … 70 71 72 73 74 … 109 » Uncommon Oncogenic Drivers in NSCLC By: Marianna Koczywas, MD View PDF SCLC Case By: Marie Suga, MD, MPH View PDF SCLC Case By: Marie Suga, MD, MPH View Video Neoadjuvant Immunotherapy Position By: Marina Garassino, MD View PDF Neoadjuvant Immunotherapy Position By: Marina Garassino, MD View Video Antibody Drug Conjugates in NSCLC By: Marina Garassino, MD View PDF How to Choose Front Line Therapy for Metastatic NSCLC By: Mark A. Socinski, MD View PDF What Is Next After Osimertinib Progression? By: Mark A. Socinski, MD View PDF What Is Next After Osimertinib Progression? By: Mark A. Socinski, MD View Video How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps? By: Mark Kris, MD View PDF How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps? By: Mark Kris, MD View Video RET, MET & NTRK Mutations in NSCLC By: Mark Socinski, MD View Video RET, MET & NTRK Mutations in NSCLC By: Mark Socinski, MD View PDF EGFRex20ins, METex14 and RET in NSCLC By: Mark Socinski, MD View PDF EGFRex20ins, METex14 and RET in NSCLC By: Mark Socinski, MD View Video NTRK and Antibody Drug Conjugates in NSCLC By: Martin Dietrich, MD, PhD View PDF ALK, ROS-1 and RET By: Martin Dietrich, MD, PhD View PDF KRAS mutant NSCLC: What is the Standard of Care Now? By: Mary Jo Fidler, MD View PDF KRAS mutant NSCLC: What is the Standard of Care Now? By: Mary Jo Fidler, MD View Video Targeted Therapy By: Matthew Gubens, MD View PDF Mesothelioma and Thymoma – Limited and Advanced Stage By: Matthew Gubens, MD View PDF Mesothelioma and Thymoma – Limited and Advanced Stage By: Matthew Gubens, MD View PDF Targeted Therapy By: Matthew Gubens, MD View Video Mesothelioma and Thymoma – Limited and Advanced Stage By: Matthew Gubens, MD View Video Oncogene-Driven NSCLC By: Matthew Gubens, MD, MS View PDF
